Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
29
ABUS Quote, Financials, Valuation and Earnings
Last price:
$3.14
Seasonality move
:
21.65%
Day range:
$3.15 - $3.25
52-week range:
$2.21 - $4.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
85.32x
P/B ratio:
5.66x
Volume:
722.3K
Avg. volume:
916.9K
1-year change:
34.6%
Market cap:
$604.5M
Revenue:
$18.1M
EPS (TTM):
-$0.43
Analysts' Opinion
-
Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Arbutus Biopharma has an estimated upside of 63.41% from its current price of $3.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.19.
Fair Value
-
According to the consensus of 0 analysts, Arbutus Biopharma has 63.41% upside to fair value with a price target of -- per share.
ABUS vs. S&P 500
-
Over the past 5 trading days, Arbutus Biopharma has underperformed the S&P 500 by -11.67% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Arbutus Biopharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arbutus Biopharma revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Arbutus Biopharma reported revenues of $1.3M.
Earnings Growth
-
Arbutus Biopharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arbutus Biopharma reported earnings per share of -$0.10.
Enterprise value:
476.7M
EV / Invested capital:
4.46x
Price / LTM sales:
85.32x
EV / EBIT:
--
EV / Revenue:
70.70x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.63x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-50.88%
Net Income Margin (TTM):
-1137.65%
Return On Equity:
-67.36%
Return On Invested Capital:
-67.36%
Operating Margin:
-1304.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $36M | $22.2M | $6.7M | $4.7M | $1.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$62.9M | -$78.5M | -$78.5M | -$21.4M | -$17.5M | |
| EBITDA | -$60.9M | -$73.4M | -$75.1M | -$19.7M | -$19.4M | |
| Diluted EPS | -$0.48 | -$0.46 | -$0.43 | -$0.12 | -$0.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $121.2M | $126.5M | $141.1M | $141.6M | $132.8M | |
| Total Assets | $131.1M | $165.6M | $203.8M | $158.6M | $140.4M | |
| Current Liabilities | $7.6M | $10.1M | $27.5M | $22.3M | $18.9M | |
| Total Liabilities | $33.8M | $35.5M | $58.3M | $39.3M | $33.6M | |
| Total Equity | $97.3M | $130.1M | $145.5M | $119.3M | $106.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$38M | -$85.6M | -$71.8M | -$21.8M | -$20.7M | |
| Cash From Investing | -$95.7M | $41.2M | $31.8M | $10.4M | -$12M | |
| Cash From Financing | $79.9M | $37.9M | $54.4M | $1.7M | $1.8M | |
| Free Cash Flow | -$38.4M | -$86.8M | -$71.9M | -$21.8M | -$20.7M | |
ABUS
Sector
Market Cap
$604.5M
$45.6M
Price % of 52-Week High
67.51%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
-6.58%
-0.74%
1-Year Price Total Return
34.6%
-31.35%
Beta (5-Year)
1.842
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$3.36
200-day SMA
Sell
Level
$3.44
Bollinger Bands (100)
Sell
Level
3.52 - 4.12
Chaikin Money Flow
Sell
Level
-496.6M
20-day SMA
Sell
Level
$3.48
Relative Strength Index (RSI14)
Sell
Level
33.12
ADX Line
Sell
Level
7.14
Williams %R
Buy
Level
-90.9091
50-day SMA
Sell
Level
$3.70
MACD (12, 26)
Sell
Level
-0.12
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
327.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.3574)
Sell
CA Score
(Annual)
Level (-1.3588)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.3748)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Stock Forecast FAQ
In the current month, ABUS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ABUS average analyst price target in the past 3 months is --.
-
Where Will Arbutus Biopharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arbutus Biopharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Arbutus Biopharma?
Analysts are divided on their view about Arbutus Biopharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arbutus Biopharma is a Sell and believe this share price will drop from its current level to --.
-
What Is Arbutus Biopharma's Price Target?
The price target for Arbutus Biopharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ABUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arbutus Biopharma is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABUS?
You can purchase shares of Arbutus Biopharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arbutus Biopharma shares.
-
What Is The Arbutus Biopharma Share Price Today?
Arbutus Biopharma was last trading at $3.14 per share. This represents the most recent stock quote for Arbutus Biopharma. Yesterday, Arbutus Biopharma closed at $3.19 per share.
-
How To Buy Arbutus Biopharma Stock Online?
In order to purchase Arbutus Biopharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.05% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.62% over the past day.
